The Administrative Core provides the infrastructure for and coordinates all activities of the MPD Research Consortium (MPD-RC). Key functions include organizational management and communication, resource allocation and management (personnel, funds,equlpment, and supplies), organization of all internal and external advisory boards, scientific and clinical trials oversight to assure regulatory cornpliarice and procedural implementation, and exetmal liaison to appropriate governmental agencies.
The specific aims of the Administrative are: 1) coordinate activities of all projects, and cores belonging to the MPD-RC;2) schedule and provide optimal staff support for all MPD-RC committees and boards and establish and staff new committees when necessary;3) assure that the use of both human subjects and animal subjects is monitored in compliance with NIH regulations for research using human subjects and animals;4) administer and oversee all budgets;5) liaison to the NCI for all matters pertaining to the MPD-RC;6) submit all applications for use of Investigational New Drugs (IND) to the U.S. Federal Drug Administration;7) report all adverse events experienced by patients participating in clinical trials to investigators, participating instituions and appropriate regulatory agencies;8) develop and negotiate contracts with pharmaceutical companies to gain access to drugs to be administered in clinical trials and obtain partial support from pharmaceutical companies for the performance of these trials;9) prepare and provide yearly progress reports to the NCI.
The Administrative Core is a critical resource which coordinates the activities of the 6 projects and other cores which comprise the MPD-RC. This core provides an organizational foundation which permits the investigators who are located at multiple geographic sites across 9 time zones to closely and effectively interact.
|Wang, Xiaoli; Haylock, David; Hu, Cing Siang et al. (2016) A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood 127:3398-409|
|Divoky, Vladimir; Song, Jihyun; Horvathova, Monika et al. (2016) Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor. J Mol Med (Berl) 94:597-608|
|Spangrude, Gerald J; Lewandowski, Daniel; Martelli, Fabrizio et al. (2016) P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells 34:67-82|
|Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution ofÂ nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12|
|Lu, Min; Xia, Lijuan; Liu, Yen-Chun et al. (2015) Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood 126:972-82|
|Wang, Xiaoli; Cho, Sool Yeon; Hu, Cing Siang et al. (2015) C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol 43:100-9.e1|
|Kovacsovics-Bankowski, Magdalena; Kelley, Todd W; Efimova, Olga et al. (2015) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol 5:28|
|Swierczek, S; Lima, L T; Tashi, T et al. (2015) Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 29:2432-4|
|Funnell, Alister P W; Prontera, Paolo; Ottaviani, Valentina et al. (2015) 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood 126:89-93|
|Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2015) Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. Haematologica 100:178-87|
Showing the most recent 10 out of 164 publications